Status:
UNKNOWN
Memantine on Aggression and Agitation of Alzheimer's Disease (AD)
Lead Sponsor:
Peking University
Collaborating Sponsors:
H. Lundbeck A/S
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
Alzheimer's disease (AD), is associated with behavioral disturbances in approximately 50% of AD patients in Beijing. Agitation, and aggression specifically, is considered the most serious noncognitive...
Eligibility Criteria
Inclusion
- Written informed consent
- Clinical diagnosis of Alzheimer's disease.
- Having at least a minimum aggression score on the Cohen-Mansfield Agitation Inventory (CMAI): a score of ≥ 4 on at least 1 aggressive item, or a score of 3 on at least 2 aggressive items, or a score of 2 on at least 3 aggressive items, or 2 aggressive items occurring at a frequency of 2 and 1 at a frequency of 3.
- Availability of a responsible family member or carer to ensure treatment compliance and provide information for informant assessments.
Exclusion
- Unavailability of a responsible family member or carer
- Severe renal impairment.
- History of seizures
- Diagnosis of any concomitant life threatening illness.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2014
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00703430
Start Date
March 1 2008
End Date
June 1 2014
Last Update
January 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Institute of Mental Health
Beijing, China, 100083